Nonsurgical cell therapy for corneal edema improves BCVA, topline results show
Click Here to Manage Email Alerts
Topline results from a phase 1 extension study show EO2002, a nonsurgical cell therapy for corneal edema, improved best corrected visual acuity at 6 months and maintained a strong safety profile, according to a press release from Emmecell.
“These findings strongly support advancing EO2002 into phase 3 trials, bringing us closer to providing a transformative, nonsurgical treatment for patients with corneal edema,” Jeffrey L. Goldberg, MD, PhD, the company’s co-founder and professor and chair of ophthalmology at Stanford University, said in the release.
In the multicenter, randomized trial, a cohort receiving 150,000 endothelial cells achieved a mean gain of 11 letters in BCVA at 6 months, with 38% of patients achieving at least a 15-letter gain, according to the release. Across all dose levels, which ranged from 150,000 cells to 1 million cells, participants demonstrated improvement in BCVA and reductions in central corneal thickness. No ocular or treatment-related serious adverse events were reported among the trial’s 30 participants.
According to the release, EO2002 uses Emmecell’s Magnetic Cell Delivery technology, which allows precise delivery of endothelial cells to the posterior cornea. Its nonsurgical approach could treat “hundreds of eyes from a single donor cornea,” the company stated.
“The ability to treat corneal edema without surgery is a game-changer for patients,” Ellen Koo, MD, study investigator and professor of ophthalmology at University of Miami’s Bascom Palmer Eye Institute, said in the release. “With EO2002, we could significantly expand access to treatment and improve outcomes for a larger population.”
Read more about
Click Here to Manage Email Alerts